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Characterization and discovery of a 
selective small molecule modulator of 







• At the end of the electron transport chain, 
energy (ATP) is generated by oxidative 
phosphorylation
• Through this process, high energy 
electrons are used in complexes I-IV to 
move protons into the inner mitochondrial 
membrane from the matrix
• The excess of protons in the inner 
membrane space is used to generate ATP 
at ATP Synthase (complex V) by shuttling 
them back into the matrix
Complex I
• Complex 1, also known as NADH dehydrogenase, 
takes two electrons from NADH, a byproduct of 
the breakdown of glucose
• Inhibiting this complex using selective inhibitors is 
known to lead to decrease reactive oxygen species 
generation
• Reactive oxygen species (ROS) are oxygen 
compounds that have unpaired electrons, making 
them highly unstable
• In the present study, the researchers produced a 
simple complex I inhibitor to prevent ROS 
generation
Reactive Oxygen Species (ROS)
• Reactive oxygen species are unstable due to the 
presence of an unpaired electron, making the 
orbitals in which they lie unstable
• Antioxidants, however, can donate electrons, 
making them stable
• If uncontrolled, reactive oxygen species can lead to 
apoptosis (programmed cell death) and 
neurodegenerative diseases like Alzheimer’s 
diseases
• ROS are also one of the theories for aging
• Complex 1 is a primary generator of ROS, making it 
a target for inhibition
Superoxide
ZCM-I-1
• ZCM-I-1 is made up of two antioxidants
• These results show that ZCM-I-1 could 
itself serve lower ROS generation
Location of ZCM-I-1 Binding
• Before this study, the location of ZCM-I-1 binding was unknown
• It was known from previous studies that ZCM-I-1 suppressed total 
ROS 
• The researchers then began to examine its role in the mitochondria
• Complexes I and III produce the greatest amounts of ROS, causing the 
researchers to focus on the binding (if present) of ZCM-I-1 to these 
complexes
• The researchers used cortical neurons for testing
Location of ZCM-I-1 Binding
• Rotenone is known to increase ROS in the mitochondria (mitoROS) at 
complex 1
• With rotenone alone, the researchers observed greater mitoROS
production
• However, ZCM-I-1 + rotenone produced lower mitoROS levels, leading 
the conclusion that ZCM-I-1 competes with rotenone has a selective 
inhibitor
• Antimycin was used to stimulate complex III by itself, and adding 
ZCM-I-1 did not lead to lower mitoROS, meaning ZCM-I-1 interacts 
with complex I alone
Specificity of Location
• Now that the researchers know that ZCM-I-1 selectively binds to 
complex I as an inhibitor, the researchers wanted to know where 
specifically it binds 
• Knowing where it binds specifically would help scientists uncover the 
“the exact pathological role of mitochondrial dysfunction, especially 
for mitochondrial reactive oxygen species associated oxidative stress”
• Thus, the researchers marked ZCM-I-1 using photoaffinity probes to 
trace it
PAL-1 and PAL-2
• PAL-1 were each individually bonded to 
ZCM-I-1, meaning that wherever ZCM-I-
1 went, PAL-1 would go also
• By photoaffinity labeling, the 
researchers were able to find where 
ZCM-I-1 bound itself to
• PAL-2 was bonded to ZCM-I-1 in a 
separate experiment
• These photoaffinity labels covalently 
bind to enzyme, and fluorescence can 
reveal where the labels bonded to
PAL-1 and PAL-2 Binding
• It was found that PAL-1 bound to NDUFS1, NDUFV1, NDUFS2, 
NDUFV2, and NDUFS6 subunits, meaning that ZCM-I-1 bound to the IF
site on complex I
• This means that ZCM-I-1 specifically binds to the IF site to inhibit 
complex 1 and lower ROS generation
ROS Decline: An Antioxidant Effect?
• So far, ZCM-I-1 has been shown to reduce ROS by binding to the IF site 
of complex I
• However, could ZCM-I-1 also serve as an antioxidant?
• When trolox and NAC (known antioxidants) were added, the total 
ROS did not decrease when compared to ZCM-I-1 alone
• Thus, it can be concluded that ZCM-I-1 affects ROS generation by 
binding to the IF site on complex I, not because it serves as an 
antioxidant
Potential Adverse Effects
• It has been established that ZCM-I-1 inhibits complex I at the IF site
• However, would this difference cause a decrease in membrane 
potential and less ATP generated?
• The researchers tested on mice nervous tissue and found that 
membrane potential and ATP levels were not affected by ZCM-I-1, 
suggesting ZCM-I-1 would be an effective drug to allow mitochondria 
to function while inhibiting the production of ROS
Conclusions So Far
• Previously it has been found that ZCM-I-1 lowered overall ROS
• This study showed that ZCM-I-1 lowered ROS by modulating the ETC 
within the mitochondria
• More specifically, the ZCM-I-1 inhibits complex I at the IF site
• However, ZCM-I-1 did not lower membrane potential
• This makes ZCM-I-1 an exciting drug to administer to alleviate 
oxidative stress and prevent mitochondrial dysfunction
Connection to Neurodegenerative Diseases
• Until now, how ROS and mitochondrial dysfunction played a role in 
Alzheimer’s disease was unknown
• Was ROS a cause of AD or an effect?
• Theoretically, if ROS were a cause of Alzheimer’s, lowering ROS using 
ZCM-I-1 would prevent the effects of Alzheimer’s
• To test thus, the researchers used 3xTg mice
• 1: AD – protein tangling
• 2: AD – protein plaques
• 3: Mitochondrial dysfunction/oxidative stress
Oxidative Stress and Alzheimer’s
• By measuring the respiration of pyruvate in 3xTg mice, the 
researchers were able to determine that continuous treatment with 
ZCM-I-1 lowered mitochondrial dysfunction
• This means that if the oxidative stress model of Alzheimer’s is true, 
ZCM-I-1 could serve as an effective tool in controlling Alzheimer’s
• However, overdosing on ZCM-I-1 could mean the electron transport 
chain is unable to function, only further leading to more 
mitochondrial dysfunction
Discussion Questions
• This paper made use of many chemical techniques to determine the 
specific binding site of a single molecule within the certain type of 
cell. Do you think the specificity of research is too great?
• Do you think we should focus on more passive agents of disease 
(ROS) or more active agents of disease (excess sugar)?
• The complexity of our cells – even our mitochondria – are great. Why 
do you think it is that we have so much interest in characterizing 
things we cannot see with the naked eye?
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